Comprehensive Report on the Investigational IL-1α Inhibitor: Bermekimab (DB14947)

1.0 Executive Summary

Bermekimab is an investigational, first-in-class biologic therapeutic agent defined as a "True Human™" monoclonal antibody. Its mechanism of action is the specific, high-affinity targeting and neutralization of Interleukin-1 alpha (IL−1α), a potent pro-inflammatory cytokine implicated in a wide range of diseases. Developed initially by XBiotech Inc., Bermekimab has undergone a complex and informative clinical development program that has ultimately refined its therapeutic potential from a broad-spectrum anti-inflammatory candidate to a highly focused asset for specific dermatological conditions.

The clinical development history of Bermekimab is characterized by a sharp divergence in outcomes across different indications. The drug demonstrated significant and clinically meaningful efficacy in Phase II trials for moderate-to-severe Hidradenitis Suppurativa (HS), a chronic and debilitating inflammatory skin disease with high unmet medical need. Notably, Bermekimab showed robust efficacy in patients who had previously failed anti-tumor necrosis factor (TNF) therapy and provided a substantial reduction in pain, a key symptom of the disease. This success contrasts starkly with its development in other areas. A Phase III trial in metastatic colorectal cancer (MCRC) was terminated, and a comprehensive Phase II program in atopic dermatitis (AD) was also halted early for futility after larger, controlled studies failed to replicate promising initial results and showed the drug to be inferior to the existing standard of care.

The therapeutic rationale for Bermekimab is predicated on blocking the inflammatory cascade initiated by IL−1α. While a limited number of secondary sources have erroneously identified its target as CD47, the overwhelming body of evidence from the developer, the acquirer, and primary scientific literature confirms its exclusive action on IL−1α. The drug has demonstrated a generally manageable safety and tolerability profile across its clinical trials, with injection site reactions being the most frequently reported drug-related adverse event.

The perceived value of Bermekimab, particularly for its potential in dermatology, was underscored in December 2019 by its acquisition by Janssen Biotech, Inc., a Johnson & Johnson company, in a deal valued at $750 million upfront with potential for future milestones. This transaction has placed the asset under the stewardship of a global leader in immunology, significantly de-risking its future development path.

Currently, Bermekimab remains an investigational agent with no marketing authorizations from any major global regulatory body, including the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). Its future appears to be focused on pivotal Phase III development for Hidradenitis Suppurativa, where it has the potential to become a valuable new therapeutic option for a patient population with limited effective treatments.

2.0 Molecular Profile and The "True Human™" Platform

The fundamental identity of Bermekimab is defined by its unique molecular characteristics and its origin from a proprietary antibody discovery platform that distinguishes it from the majority of monoclonal antibodies in clinical development. A precise understanding of its structure and provenance is critical to appreciating its therapeutic hypothesis and potential clinical advantages.

2.1 Identification and Physicochemical Properties

Bermekimab is a biologic drug, specifically a whole, recombinant human monoclonal antibody of the Immunoglobulin G1-kappa (IgG1κ) isotype.[1] It is produced in mammalian Chinese Hamster Ovary (CHO) cells and formulated as a sterile liquid solution for intravenous (IV) or subcutaneous (SC) administration.[4] During its development, it has been referred to by several names and codes, including the laboratory designation MABp1, the proposed trade name Xilonix (used during its oncology trials), and the Janssen development code JNJ-77474462.[1] Its key physicochemical properties and identifiers are consolidated in Table 1.

Table 1: Key Identifiers and Physicochemical Properties of Bermekimab

Parameter	Value	Source(s)
DrugBank ID	DB14947	1
CAS Number	1401965-15-8	1
UNII	N6SVN735GY	1
KEGG ID	D11253	1
ATC Code	L01FX11	1
Type	Biotech, Whole Monoclonal Antibody	1
Source	Human	1
Isotype	Human IgG1κ	2
Developer Codes	MABp1, JNJ-77474462, RA-18C3	1
Molecular Formula	C6464​H10024​N1736​O2000​S44​	1
Molar Mass	145468.09 g/mol (approx. 145.5 kDa)	1

2.2 A "True Human™" Antibody

Bermekimab originated from the proprietary "True Human™" antibody discovery platform developed by XBiotech Inc..[10] This platform represents a distinct approach to antibody generation that differs fundamentally from conventional methods such as hybridoma technology, phage display, or the use of transgenic animals. Instead of being engineered or "humanized" in vitro to reduce immunogenicity, Bermekimab was cloned directly from a naturally occurring peripheral blood B lymphocyte isolated from a healthy human donor.[13]

The heavy and light chain amino acid sequences of Bermekimab are therefore identical to those of an antibody that has undergone natural affinity maturation and immunological selection within the human immune system.[13] The developer posits that this unique origin is a significant advantage. Because the antibody's structure is entirely native to the human body, it is expected to be viewed as "self" by a patient's immune system. This characteristic is hypothesized to result in minimal to no immunogenicity, thereby reducing the risk of developing anti-drug antibodies (ADAs).[12] The absence of a significant ADA response is a critical attribute for any biologic intended for chronic use, as ADAs can neutralize a drug's activity, accelerate its clearance from the body, and, in some cases, cause adverse immune reactions. The clinical development program for Bermekimab has thus far supported this hypothesis, with reports indicating that no treatment-emergent ADAs specific to the drug have been identified in patients.[14] This low immunogenicity potential was likely a key factor in the valuation of the asset during its acquisition, as it serves to de-risk a major potential point of failure common to long-term biologic therapies.

3.0 Mechanism of Action and Pharmacological Rationale

The therapeutic strategy of Bermekimab is centered on the targeted modulation of a specific inflammatory pathway. A definitive understanding of its molecular target is essential for interpreting its clinical trial results and assessing its future potential.

3.1 Primary Target: Definitive Analysis of Interleukin-1 Alpha (IL-1α) Neutralization

The overwhelming and conclusive body of evidence from primary sources confirms that Bermekimab is a high-affinity monoclonal antibody that specifically targets and neutralizes the pro-inflammatory cytokine Interleukin-1 alpha (IL−1α).[1] It functions as a potent blocker of

IL−1α's biological activity, thereby inhibiting the downstream inflammatory processes that this cytokine mediates.[3] The binding affinity has been measured at approximately

211±31 pM.[14]

It is critical to address and resolve conflicting information present in a small number of secondary, non-primary sources. Several articles, primarily from a single commercial blog, incorrectly identify the molecular target of Bermekimab as CD47, a receptor involved in immune checkpoint regulation.[17] This assertion is in direct contradiction to the extensive documentation provided by the drug's developer (XBiotech), its current owner (Janssen), official clinical trial registries, and numerous peer-reviewed scientific publications.[3] There is no evidence to suggest that Bermekimab has a dual-targeting mechanism or any activity against CD47. The repeated mention of CD47 in these isolated sources appears to be an error, possibly arising from a misunderstanding or a conflation with other immunotherapeutic agents. For the purposes of this report and any future evaluation,

IL−1α should be considered the sole and definitive molecular target of Bermekimab.

3.2 The Role of IL-1α in Pathophysiology

IL−1α is a member of the IL-1 family of cytokines and functions as a key "alarmin"—a molecule released by stressed or necrotic cells that signals tissue damage and initiates a sterile inflammatory response.[3] Its function is largely mediated through the IL-1 receptor, which is expressed on a wide variety of cells, including innate and adaptive immune cells as well as non-immune tissues.[13] Upon activation, leukocytes such as macrophages and neutrophils, as well as structural cells like keratinocytes, produce and release

IL−1α, which triggers a potent inflammatory cascade associated with effects like the induction of matrix metalloproteinases and the infiltration of inflammatory cells into tissue.[13] The pharmacological rationale for targeting

IL−1α with Bermekimab is tailored to the specific pathophysiology of the diseases in which it has been investigated:

• Dermatology (Atopic Dermatitis & Hidradenitis Suppurativa): The skin is a significant reservoir of pre-formed IL−1α, particularly within keratinocytes.[3] In conditions like atopic dermatitis (AD), it is hypothesized that disruption of the skin barrier—a hallmark of the disease—leads to the release of this stored IL−1α, which acts as an initial trigger for the inflammatory response.[13] In hidradenitis suppurativa (HS), high concentrations of IL-1 have been found directly within the drainage from severe lesions, providing a direct link between the cytokine and the disease's inflammatory manifestations.[22]
• Oncology (Metastatic Colorectal Cancer): Within the tumor microenvironment, IL−1α is known to be a pleiotropic factor that promotes tumor progression. It contributes to neoangiogenesis (the formation of new blood vessels), remodeling of the extracellular matrix to facilitate invasion, and metastasis.[6] Furthermore, systemic inflammation driven by cytokines like IL−1α is a primary cause of cancer-related cachexia, a debilitating syndrome of weight loss, fatigue, and anorexia that severely impacts patient quality of life and prognosis.[6]
• Systemic Sclerosis (SSc): In SSc, a disease characterized by fibrosis and vasculopathy, evidence suggests that over-production of IL−1α by fibroblasts contributes directly to the pro-fibrotic process. IL−1α is also implicated in mediating the vasculopathy by bridging platelets to the vascular endothelium.[16]

3.3 Pharmacokinetics (PK) and Pharmacodynamics (PD)

The pharmacokinetic and pharmacodynamic profile of Bermekimab has been characterized in several early-phase studies, although some planned analyses in later trials were not completed due to early study terminations.

A Phase I study (NCT03047317) was conducted specifically to evaluate the pharmacokinetics of a single 7.5 mg/kg intravenous dose in healthy volunteers. The primary endpoints of this study were to determine key PK parameters such as peak plasma concentration (Cmax​), time to peak plasma concentration (Tmax​), half-life (t1/2​), and area under the plasma concentration-time curve (AUC) over a two-week period.[24]

In a separate first-in-human Phase I dose-escalation study conducted in patients with advanced cancers, pharmacokinetic data were found to be consistent across all dose levels. The highest dosing cohort in this study (3.75 mg/kg) exhibited an average peak serum concentration of 80 micrograms per milliliter and a half-life of approximately 3 days.[25] Importantly, these data showed no evidence of drug accumulation or increased clearance with escalating doses, suggesting linear and predictable pharmacokinetics within the dose range studied.[25]

Pharmacokinetic and immunogenicity assessments were included as secondary or exploratory objectives in the more advanced Phase II trials for both AD (NCT04990440, LUNA) and HS (NCT03512275).[28] However, due to the premature termination of the LUNA trial, the planned PK data collection and analysis could not be fully performed.[29] To further elucidate the drug's biological effects, particularly in the skin, a novel human ex vivo skin pharmacodynamic assay was developed. This model was used to assess proteomic and transcriptomic changes in skin tissue following exposure to Bermekimab. The results from this assay demonstrated that the drug effectively reduced downstream molecular responses associated with skin injury and inflammation, providing a direct mechanistic link between target engagement and tissue-level effects.[13]

4.0 The Clinical Development Program: A Tale of Divergent Outcomes

The clinical development journey of Bermekimab has been extensive and informative, spanning multiple therapeutic areas and phases of investigation. This history is not one of uniform success but rather a compelling narrative of portfolio attrition, where initial broad exploration gave way to a highly focused strategy based on divergent clinical outcomes. The program's trajectory illustrates the rigorous process of identifying a drug's true therapeutic niche, with clear failures in oncology and atopic dermatitis ultimately highlighting its significant potential in hidradenitis suppurativa. Table 2 provides a high-level summary of the major clinical trials that have defined this path.

Table 2: Summary of Major Clinical Trials for Bermekimab

NCT Identifier	Indication	Phase	Status	Key Design	High-Level Outcome
NCT03047317	Healthy Volunteers	1	Completed	Open-Label, Single Group	Assessed pharmacokinetics of a single IV dose.24
NCT01767857	Metastatic Colorectal Cancer (MCRC)	3	Terminated	Randomized, Placebo-Controlled	Program discontinued; did not lead to regulatory approval.32
NCT03496974	Atopic Dermatitis (AD)	2	Completed	Open-Label, Dose-Escalation	Showed promising initial efficacy, prompting further studies.13
NCT04021862	Atopic Dermatitis (AD)	2	Completed	Randomized, Placebo-Controlled	Met primary endpoint but overall efficacy signal was modest.13
NCT04791319	Atopic Dermatitis (AD)	2b	Terminated	Randomized, Placebo- and Active-Comparator-Controlled	Terminated early for futility; inferior to placebo and active comparator.13
NCT04990440	Atopic Dermatitis (AD)	2a	Terminated	Randomized, Placebo-Controlled (IV Dosing)	Terminated early following failure of NCT04791319.13
NCT03512275	Hidradenitis Suppurativa (HS)	2	Completed	Open-Label, Confirmatory	Demonstrated high efficacy (HiSCR) and significant pain reduction.28
NCT04019041	Hidradenitis Suppurativa (HS)	2	Completed	Randomized, Placebo-Controlled	Further evaluated efficacy and safety in a controlled setting.36
N/A (LIGHT)	Systemic Sclerosis (SSc)	2	Completed	Randomized, Placebo-Controlled	Met primary endpoint, showing global improvement.16

4.1 Foundational Phase I Studies

The clinical journey of Bermekimab began with foundational Phase I studies designed to establish its safety, tolerability, and pharmacokinetic profile. The first-in-human trial was an open-label, 3+3 dose-escalation study in patients with various solid tumors that were refractory to standard-of-care treatments. This study successfully established an initial safety profile, identified a maximum tolerated dose of 3.75 mg/kg, and provided the first evidence of potential anti-tumor activity.[1] Subsequently, a dedicated Phase I pharmacokinetic study (NCT03047317) was conducted in six healthy volunteers to precisely characterize the drug's behavior in the absence of underlying disease. This trial involved administering a single 7.5 mg/kg IV infusion and conducting intensive blood sampling over two weeks to define key PK parameters.[24] Together, these early studies provided the necessary safety and dosing information to proceed with broader Phase II development.

4.2 Investigation in Inflammatory Dermatoses

The most extensive and ultimately most consequential part of Bermekimab's development has been in chronic inflammatory skin diseases, where its trajectory in atopic dermatitis and hidradenitis suppurativa followed starkly different paths.

4.2.1 Atopic Dermatitis (AD): From Initial Promise to Clinical Futility

The investigation of Bermekimab for AD was based on the strong scientific rationale that IL−1α released from damaged skin could be an initiator of the disease's inflammatory cycle.

• Study 1 (NCT03496974): The initial foray into AD was a Phase II open-label, dose-escalation study that generated considerable optimism. In the high-dose cohort (400 mg weekly), the results were striking: after just seven weeks of treatment, 71% of patients achieved at least a 75% reduction in their Eczema Area and Severity Index (EASI) score (a measure known as EASI-75). This was accompanied by rapid and profound reductions in patient-reported itch (71% reduction) and pain (84% reduction).[13] These results were particularly noteworthy for their speed and magnitude compared to the existing standard of care at the time.[33]
• Study 2 (NCT04021862): Building on this success, the first randomized, double-blind, placebo-controlled Phase II study was launched to provide more rigorous evidence. The results of this trial were more equivocal. While the primary endpoint was met—a statistically significant greater proportion of patients on the weekly 400 mg dose achieved EASI-75 at week 16 compared to placebo (34.5% vs. 13.8%)—the overall efficacy signal was less robust than in the open-label study. The bi-weekly dosing arm did not show a significant difference from placebo, and improvements in other key secondary endpoints, such as itch reduction, were not statistically significant.[13]
• GENESIS Trial (NCT04791319): To definitively assess its place in the AD treatment landscape, Janssen initiated the GENESIS trial, a large Phase IIb study. This trial was designed with maximum rigor, including randomization, double-blinding, a placebo arm, and an active-comparator arm using dupilumab, the well-established standard of care for moderate-to-severe AD. The trial proved to be the decisive end for the AD program. An independent interim analysis committee recommended terminating the study early for futility.[13] The analysis revealed that Bermekimab, at both doses tested, was not providing a clinical benefit significantly greater than placebo and was substantially less effective than dupilumab.[13]
• LUNA Trial (NCT04990440): A smaller Phase IIa study designed to evaluate an intravenous formulation of Bermekimab in AD was also underway. Following the definitive negative outcome of the much larger GENESIS trial, the LUNA study was also terminated early.[13]

The failure of Bermekimab in AD, particularly in a head-to-head comparison with an IL-4/IL-13 inhibitor, provides a crucial lesson in the specific pathophysiology of the disease. While IL−1α is undeniably involved in skin inflammation, these results strongly suggest that it is not the dominant or rate-limiting pathway driving AD. The IL-4 and IL-13 signaling axis appears to be a more critical and therapeutically tractable target for this particular condition.

4.2.2 Hidradenitis Suppurativa (HS): A Viable Therapeutic Avenue

In stark contrast to the AD program, the investigation of Bermekimab in HS has yielded consistently positive and promising results, establishing it as the drug's most viable therapeutic indication.

• Phase II Open-Label Study (NCT03512275): This multicenter, open-label confirmatory study was designed to assess the efficacy of a 400 mg weekly subcutaneous dose in two distinct patient cohorts: those who had never received anti-TNF therapy and a more difficult-to-treat group who had previously failed such treatment. The results were highly encouraging. By week 12, a high percentage of patients in both groups achieved the primary endpoint of Hidradenitis Suppurativa Clinical Response (HiSCR), with rates of 61% in the anti-TNF naïve group and 58% to 63% in the anti-TNF failure group.[28] A pivotal finding from this study was the drug's profound impact on pain. Between 67% and 72% of patients across the cohorts achieved a clinically meaningful reduction in pain by week 12.[35] This is a key differentiator, as pain is a paramount and often poorly managed symptom of HS, and the existing approved biologic therapy was shown to reduce pain only when used in combination with oral antibiotics, which were not permitted in this study.[44]
• Phase II Randomized, Placebo-Controlled Study (NCT04019041): To confirm these findings in a controlled setting, a randomized, double-blind, placebo-controlled Phase II study was conducted. This trial used HiSCR at week 12 as its primary endpoint and included various dosing regimens.[36] While a full peer-reviewed publication of the results is not yet available, data posted to the clinical trial registry confirm the study's completion and evaluation of multiple efficacy and patient-reported outcomes.[37] The consistent positive signals from the HS program have solidified it as the lead indication for Bermekimab.

4.3 The Oncology Program: The Terminated Phase III Colorectal Cancer Study

Before its focus shifted to dermatology, Bermekimab (under the name Xilonix) was advanced into late-stage trials for oncology. The primary indication was for the treatment of advanced, symptomatic metastatic colorectal cancer (MCRC), where the therapeutic goal was not just tumor response but also amelioration of cancer-related symptoms and cachexia.

• XCITE Trial (NCT01767857): This was a pivotal Phase III, double-blind, placebo-controlled clinical study.[1] In collaboration with the European Medicines Agency's Scientific Advice Working Group, XBiotech developed a novel composite primary endpoint that combined an objective measure of lean body mass with patient-reported outcomes for pain, fatigue, and anorexia.[23] While the company reported that a European Phase III study met its primary and secondary endpoints, the overall program was ultimately terminated and did not result in a marketing approval in any jurisdiction.[32] Analysis of study data suggested a potential predictive biomarker: patients with lower baseline levels of the endogenous IL-1 receptor antagonist ( IL−1Ra) were found to be more responsive to Bermekimab treatment, indicating that the balance of pro- and anti-inflammatory IL-1 signaling could influence therapeutic outcomes.[20]

4.4 Exploration in Other Immune-Mediated Diseases

The broad anti-inflammatory potential of targeting IL−1α led to the exploration of Bermekimab in several other immune-mediated diseases, although these programs did not advance as far as those in dermatology or oncology.

• Systemic Sclerosis (SSc): The LIGHT trial was a proof-of-concept, double-blind, randomized clinical trial investigating Bermekimab in advanced SSc. The study met its primary endpoint, with 80% of Bermekimab-treated patients achieving global improvement compared to only 20% of placebo-treated patients. The benefits were most pronounced in reducing inflamed joints and improving lung function.[16]
• Other Conditions: Bermekimab was also under clinical development for Rheumatoid Arthritis (in Phase II) and had been investigated for Psoriasis.[5] However, development for these and other indications, such as Type 2 diabetes and vascular restenosis, was ultimately discontinued as the company's strategic focus narrowed.[8]

5.0 Integrated Analysis of Efficacy, Safety, and Tolerability

A comprehensive evaluation of an investigational drug requires an integrated analysis of its demonstrated efficacy across different contexts, its safety profile as observed in clinical trials, and any potential for drug interactions. For Bermekimab, this analysis reveals a therapeutic agent with a highly indication-specific efficacy profile and a generally manageable safety profile.

5.1 Synthesis of Efficacy Across Indications

The clinical efficacy of Bermekimab is best understood as a spectrum of outcomes that is highly dependent on the underlying pathophysiology of the target disease.

• Strong Efficacy in Hidradenitis Suppurativa: In HS, Bermekimab has demonstrated robust and clinically meaningful efficacy. Across Phase II studies, approximately 60% of patients achieved the composite HiSCR endpoint, a stringent measure of disease improvement accepted by regulatory authorities.[35] This efficacy was notably maintained even in a difficult-to-treat population of patients who had previously failed anti-TNF therapy. The most differentiating aspect of its efficacy profile in HS is the significant and rapid reduction in pain, with around 70% of patients reporting clinically important relief.[35] This potent analgesic and anti-inflammatory effect addresses one of the most debilitating symptoms of the disease.
• Lack of Efficacy in Atopic Dermatitis: In stark contrast, the efficacy of Bermekimab in AD proved to be insufficient. While an initial open-label study was promising, larger, more rigorous placebo-controlled trials failed to confirm a significant clinical benefit. In the head-to-head GENESIS trial, Bermekimab was not superior to placebo and was significantly less effective than the active comparator, dupilumab.[13] This failure suggests that the IL−1α pathway, while involved in skin inflammation, is not a primary driver of AD pathology.
• Modest Efficacy in Metastatic Colorectal Cancer: In MCRC, the drug's effect was measured by a novel composite endpoint focused on lean body mass and symptom control rather than traditional tumor response. While the Phase III trial reportedly met this primary endpoint (33% response rate vs. 19% for placebo), this measure of clinical benefit did not ultimately translate into a successful regulatory outcome, and the program was discontinued.[23]

5.2 Comprehensive Safety Profile

Across the clinical development program, Bermekimab has demonstrated a consistent and generally manageable safety and tolerability profile.

• Adverse Events (AEs): The most frequently reported adverse event considered related to Bermekimab administration is injection site reactions, which are typically mild to moderate and include symptoms such as redness, swelling, and soreness.[22] In dermatological studies, other commonly reported non-serious AEs included upper respiratory infections and nausea.[22] In the GENESIS trial for AD, the overall rate of AEs was higher in the Bermekimab group (66%) compared to both placebo (54.5%) and dupilumab (50.8%).[50] Table 3 summarizes the adverse event profile from key studies.
• Serious Adverse Events (SAEs): The incidence of serious adverse events has generally been low and comparable to placebo in most studies. In the Phase III MCRC trial, the rate of SAEs was not significantly different between the Bermekimab and placebo groups (23% vs. 32%).[23] In the GENESIS trial, four SAEs were reported in the combined Bermekimab arms, while none were reported in the placebo or dupilumab arms; however, investigators deemed none of these SAEs to be related to the study drug.[50]
• Material Safety Data Sheet (MSDS) Information: For handling of the pure, undiluted active pharmaceutical ingredient, the MSDS classifies Bermekimab as toxic and a moderate to severe irritant to the skin and eyes. It advises that handling should only be performed by personnel trained in the management of potent pharmaceutical ingredients.[51] It also notes that thermal decomposition can emit toxic fumes, such as carbon monoxide and nitrogen oxides. These warnings pertain to occupational safety during manufacturing and preparation and are not reflective of the clinical safety profile of the final diluted drug product administered to patients.[51]

Table 3: Summary of Reported Adverse Events Across Key Phase II Studies

Adverse Event	Frequency in Bermekimab Arm (%)	Frequency in Placebo Arm (%)	Frequency in Active Comparator Arm (%)	Relevant Study (Indication)	Source(s)
Any Adverse Event	66.0	54.5	50.8 (Dupilumab)	GENESIS (AD)	50
Injection Site Reactions	High Incidence (not quantified)	N/A	N/A	HS Open-Label	22
Nausea	Common (not quantified)	N/A	N/A	HS Open-Label	22
Serious Adverse Events	4 SAEs (not drug-related)	0	0 (Dupilumab)	GENESIS (AD)	50

5.3 Clinically Relevant Drug Interactions

An analysis of potential drug-drug interactions based on established pharmacological principles indicates several classes of medications that may pose a risk when co-administered with Bermekimab. This information is derived from comprehensive drug interaction databases.[49]

• Increased Risk of Adverse Effects with Other Biologics: As an immunomodulatory agent, combining Bermekimab with other monoclonal antibodies (e.g., amivantamab, anifrolumab, cetuximab, dupilumab) could potentially increase the overall risk or severity of adverse effects, likely due to cumulative effects on the immune system.
• Increased Risk of Methemoglobinemia: There is a theoretical risk of an increased incidence of methemoglobinemia when Bermekimab is combined with certain local anesthetics (e.g., benzocaine, bupivacaine, cocaine) and other specific drugs like ambroxol and diphenhydramine.
• Increased Thrombogenic Activity: Co-administration with estrogen-containing products (e.g., conjugated estrogens, diethylstilbestrol) may increase the thrombogenic activities of Bermekimab.
• Increased Risk of Thrombosis: A specific warning exists for an increased risk of thrombosis when combined with the erythropoiesis-stimulating agent darbepoetin alfa.
• Interaction with Vaccines: As with many immunosuppressive or immunomodulatory therapies, Bermekimab may decrease the therapeutic efficacy of live attenuated vaccines, such as the Ebola Zaire vaccine.

6.0 Corporate and Regulatory Trajectory

The journey of Bermekimab from a novel discovery to a high-value clinical asset is a compelling case study in biopharmaceutical strategy, culminating in a major acquisition and a clarified development path. Its regulatory status remains pre-approval, a critical point of distinction from other similarly named biologics on the market.

6.1 Genesis at XBiotech Inc.

Bermekimab was discovered and initially developed by XBiotech Inc., a biopharmaceutical company headquartered in Austin, Texas.[1] The company's core focus is its proprietary "True Human™" antibody platform, which aims to develop therapies derived from natural human immunity to achieve superior safety and efficacy.[5] Bermekimab was the lead asset from this platform, and its development timeline shows a strategic pivot towards dermatology in 2018, following promising early results in skin conditions.[11]

6.2 The $750 Million Acquisition by Janssen Biotech, Inc.

In a landmark event for both companies, Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, entered into a definitive agreement to acquire all rights to Bermekimab in December 2019. The acquisition was completed on December 30, 2019.[10]

• Deal Terms: The financial terms of the agreement were substantial, reflecting the high perceived value of the asset. Janssen made an upfront cash payment of $750 million to XBiotech.[12] The agreement also includes provisions for up to $600 million in additional milestone payments, contingent on Janssen successfully pursuing and receiving commercialization authorizations for Bermekimab in indications outside of dermatology.[10]
• Transitional and Strategic Agreements: The deal was structured to ensure a smooth transition of the development program. XBiotech agreed to continue manufacturing clinical supplies of Bermekimab for Janssen through December 2023 under a manufacturing supply agreement.[12] Additionally, XBiotech was contracted to provide clinical trial operation services to complete the two ongoing Phase II studies in AD and HS.[10]
• Retained Rights by XBiotech: A crucial and strategic component of the deal was the retention of certain rights by XBiotech. While Janssen acquired all rights to the Bermekimab molecule itself, XBiotech remains free to use its "True Human™" platform to discover and develop new and distinct anti-IL−1α antibody therapeutics for all non-dermatological diseases.[10]

The timing and structure of this acquisition point to a highly strategic, asset-centric purchase by Janssen. The deal was finalized after the failure of the MCRC program was known and as the clinical picture in dermatology was becoming clearer, with strong positive signals in HS contrasting with emerging uncertainty in AD. By structuring the milestone payments to be contingent on non-dermatological indications, Janssen effectively placed its $750 million valuation squarely on the drug's potential in dermatology, primarily HS, while allowing XBiotech to retain the higher-risk, yet still potentially valuable, opportunity to exploit the anti-IL−1α mechanism in other disease areas.

6.3 Current Regulatory Status and Clarification

It must be stated unequivocally that Bermekimab is an investigational drug. As of this report, it has not received marketing approval from the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or the Australian Therapeutic Goods Administration (TGA).[56] It cannot be prescribed for clinical use outside of a formal clinical trial.

• Distinction from Bimekizumab: It is critically important to distinguish Bermekimab from a similarly named but entirely different drug: bimekizumab (trade name Bimzelx). Bimekizumab is a humanized monoclonal antibody that targets two other cytokines, IL−17A and IL−17F.[59] Unlike Bermekimab, bimekizumab is an approved drug and has received marketing authorization from the FDA, EMA, and TGA for the treatment of several inflammatory conditions, including plaque psoriasis and, notably, hidradenitis suppurativa.[59] The similar nonproprietary names, the overlap in one of the target indications (HS), and the fact that both are biologics for inflammatory skin disease create a significant potential for confusion. Any assessment of Bermekimab's status must carefully avoid conflating it with the approved drug bimekizumab.

7.0 Expert Analysis and Future Outlook

The extensive development history of Bermekimab provides a rich dataset from which to conduct a critical analysis and project its future trajectory. The journey of this "True Human™" antibody from a broadly investigated anti-inflammatory agent to a focused dermatological asset offers valuable insights into targeted therapy, disease pathophysiology, and pharmaceutical strategy.

7.1 Critical Assessment of the Clinical Program

The divergent outcomes of the Bermekimab clinical program underscore a fundamental principle of modern drug development: the success of a targeted therapy is as dependent on the specific biology of the disease as it is on the potency of the drug.

The "tale of two diseases"—the success in Hidradenitis Suppurativa versus the failure in Atopic Dermatitis—is particularly instructive. While both are chronic inflammatory skin disorders, their underlying immunopathology is distinct. The robust efficacy of Bermekimab in HS suggests that the IL−1α pathway is a critical, and perhaps dominant, driver of the disease's inflammatory and pain-related manifestations. The high concentrations of IL-1 found in HS lesions support this hypothesis, indicating that blocking this cytokine creates a significant therapeutic effect.[22] Conversely, the failure in AD, especially when compared directly to the efficacy of the

IL−4/IL−13 inhibitor dupilumab, indicates that IL−1α is likely a secondary or redundant pathway in the complex inflammatory network of that disease.[13]

In oncology, the MCRC program's use of a novel composite endpoint focused on quality of life and symptom control was an innovative attempt to measure clinical benefit in a patient population with advanced disease.[23] However, the termination of the program suggests that this approach, while patient-centric, may have been insufficient to meet the high bar for regulatory approval in oncology, which typically relies on more established endpoints like overall survival or progression-free survival.

7.2 Future Prospects in Dermatology

The future of the Bermekimab molecule itself now lies firmly in dermatology, under the stewardship of Janssen. The outlook for its development in Hidradenitis Suppurativa is highly positive for several reasons:

1. High Unmet Need: HS is a debilitating disease with limited approved therapeutic options, particularly for patients who have failed initial biologic therapy.[35]
2. Strong Phase II Data: The drug has demonstrated robust efficacy on the accepted regulatory endpoint (HiSCR) in a difficult-to-treat patient population.[35]
3. Differentiated Profile: Its profound effect on pain is a key clinical differentiator that could drive significant patient and physician preference. The ability to achieve pain reduction without concomitant antibiotics is a notable advantage over the current standard of care.[44]
4. Major Pharmaceutical Backing: Janssen is a global leader in immunology and has the deep expertise and financial resources required to conduct the large, global Phase III pivotal trials necessary for regulatory submission and to successfully commercialize the product upon approval.[19]

The logical next step in Bermekimab's development is the initiation of one or more large-scale Phase III trials in patients with moderate-to-severe HS. These trials will be designed to confirm the Phase II findings and build the comprehensive safety and efficacy database required for marketing authorization applications to the FDA, EMA, and other global health authorities.

7.3 Potential for Non-Dermatological Indications

While Janssen's acquisition was focused on dermatology, the story of the anti-IL−1α mechanism is not over. The deal structure, which allows XBiotech to develop new anti-IL−1α antibodies for non-dermatological indications, represents a potential "second act".[12] Now well-capitalized from the sale, XBiotech is positioned to leverage the extensive biological and clinical learnings from the Bermekimab program. The company can apply this knowledge to develop next-generation therapeutics targeting the same pathway for diseases where

IL−1α is strongly implicated, such as in cardiovascular diseases, rheumatological disorders, or specific oncology settings, potentially using a biomarker-driven approach based on the earlier findings related to IL−1Ra levels.[10]

7.4 Concluding Remarks

In conclusion, Bermekimab is a scientifically compelling, first-in-class investigational antibody that has evolved into a highly focused clinical asset. Its development provides a powerful case study in the specificity of targeted therapies, demonstrating that even a potent drug is only effective when applied to a disease where its target is a critical driver of pathology. The acquisition by Janssen has dramatically de-risked its path to market for Hidradenitis Suppurativa, transforming it from a promising candidate at a smaller biotech into a key pipeline asset for a major pharmaceutical company. As such, Bermekimab is one of the most important therapeutics to watch in the evolving landscape of treatments for chronic inflammatory skin disease.

Works cited

1. Bermekimab - Wikipedia, accessed September 23, 2025, https://en.wikipedia.org/wiki/Bermekimab
2. Research Grade Bermekimab_Datasheet - abinScience, accessed September 23, 2025, https://www.abinscience.com/index/pdf?id=383
3. NCT04988308 | A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa | ClinicalTrials.gov, accessed September 23, 2025, https://clinicaltrials.gov/study/NCT04988308
4. Bermekimab (Anti-IL-1a) Interleukins antibody | Read Reviews & Product Use Citations, accessed September 23, 2025, https://www.selleckchem.com/products/bermekimab-anti-il-1a.html
5. Bermekimab by XBiotech for Rheumatoid Arthritis: Likelihood of Approval, accessed September 23, 2025, https://www.pharmaceutical-technology.com/data-insights/bermekimab-xbiotech-rheumatoid-arthritis-likelihood-of-approval/
6. Bermekimab (MABp1) | IL-1α Antibody - MedchemExpress.com, accessed September 23, 2025, https://www.medchemexpress.com/bermekimab.html
7. NCT04791319 | A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatitis | ClinicalTrials.gov, accessed September 23, 2025, https://clinicaltrials.gov/study/NCT04791319
8. Bermekimab - Janssen Biotech - AdisInsight - Springer, accessed September 23, 2025, https://adisinsight.springer.com/drugs/800031806
9. Bermekimab (MABp1) | CAS 1401965-15-8 - AbMole BioScience, accessed September 23, 2025, https://www.abmole.com/products/bermekimab.html
10. XBiotech Announces Agreement to Sell True Human Antibody Bermekimab Targeting IL-1a to Janssen, accessed September 23, 2025, https://investors.xbiotech.com/news-releases/news-release-details/xbiotech-announces-agreement-sell-true-human-antibody-bermekimab/
11. XBiotech: Home, accessed September 23, 2025, https://www.xbiotech.com/
12. XBiotech Closes on Sale of True Human Antibody Bermekimab to Janssen, accessed September 23, 2025, https://investors.xbiotech.com/node/8456/pdf
13. Interleukin-1α inhibitor bermekimab in patients with atopic dermatitis: randomized and nonrandomized studies - ResearchGate, accessed September 23, 2025, https://www.researchgate.net/publication/383565794_Interleukin-1a_inhibitor_bermekimab_in_patients_with_atopic_dermatitis_randomized_and_nonrandomized_studies
14. NCT04019041 - ClinicalTrials.gov, accessed September 23, 2025, https://cdn.clinicaltrials.gov/large-docs/41/NCT04019041/Prot_000.pdf
15. Interleukin-1α inhibitor bermekimab in patients with atopic dermatitis: randomized and nonrandomized studies - PMC, accessed September 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11364570/
16. A randomized clinical trial of bermekimab treatment for clinical improvement of systemic sclerosis - PMC, accessed September 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10481358/
17. www.assaygenie.com, accessed September 23, 2025, https://www.assaygenie.com/blog/bermekimab-unveiling-the-role-of-anti-cd47-in-hidradenitis-suppurativa-and-atopic-dermatitis/#:~:text=What%20is%20the%20mechanism%20of,skin%20conditions%20and%20potentially%20cancer.
18. Bermekimab: Unveiling the Role of Anti-CD47 in Hidradenitis Suppurativa and Atopic Dermatitis - Assay Genie, accessed September 23, 2025, https://www.assaygenie.com/blog/bermekimab-unveiling-the-role-of-anti-cd47-in-hidradenitis-suppurativa-and-atopic-dermatitis/
19. Janssen to Acquire Investigational Bermekimab from XBiotech, accessed September 23, 2025, https://www.jnj.com/media-center/press-releases/janssen-to-acquire-investigational-bermekimab-from-xbiotech
20. Interleukin-1 receptor antagonist levels predict favorable outcome after bermekimab, a first-in-class true human interleukin-1α antibody, in a phase III randomized study of advanced colorectal cancer - PubMed Central, accessed September 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6350690/
21. XBiotech Announces First Patient Enrolled in Placebo-Controlled Clinical Study Evaluating Its anti-IL-1 Therapy Bermekimab in Patients with Atopic Dermatitis (Eczema), accessed September 23, 2025, https://investors.xbiotech.com/news-releases/news-release-details/xbiotech-announces-first-patient-enrolled-placebo-controlled/
22. New drug shows promise for Hidradenitis Suppurativa treatment - HS Foundation, accessed September 23, 2025, https://www.hs-foundation.org/bermekimab-shows-promise-for-hidradenitis-suppurativa
23. MABp1 as a novel antibody treatment for advanced colorectal cancer: A randomised, double-blind, placebo-controlled, phase 3 study | Request PDF - ResearchGate, accessed September 23, 2025, https://www.researchgate.net/publication/312356728_MABp1_as_a_novel_antibody_treatment_for_advanced_colorectal_cancer_A_randomised_double-blind_placebo-controlled_phase_3_study
24. Study Details | NCT03047317 | A Pharmacokinetic Study of MABp1 ..., accessed September 23, 2025, https://clinicaltrials.gov/study/NCT03047317
25. Abstract A211: A phase I study of MABp1, a first-in-human, first-true human monoclonal antibody against the IL-1 in patients with advanced cancers. | Molecular Cancer Therapeutics - AACR Journals, accessed September 23, 2025, https://aacrjournals.org/mct/article/10/11_Supplement/A211/238401/Abstract-A211-A-phase-I-study-of-MABp1-a-first-in
26. MABp1, a first-in-class true human antibody targeting interleukin-1α, accessed September 23, 2025, https://mdanderson.elsevierpure.com/en/publications/mabp1-a-first-in-class-true-human-antibody-targeting-interleukin-
27. Anti–Interleukin-1 Alpha Antibody MABp1 Is Well ... - The ASCO Post, accessed September 23, 2025, https://ascopost.com/News/16178
28. NCT03512275 | A Study of Bermekimab in Patients With Hidradenitis Suppurativa, accessed September 23, 2025, https://clinicaltrials.gov/study/NCT03512275?term=NCT02643654%20NCT03512275%20NCT04019041%20NCT04988308&rank=3
29. NCT04990440 | A Study of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis | ClinicalTrials.gov, accessed September 23, 2025, https://www.clinicaltrials.gov/study/NCT04990440
30. Study Details | NCT04990440 | A Study of Bermekimab for the ..., accessed September 23, 2025, https://clinicaltrials.gov/study/NCT04990440
31. Interleukin-1α inhibitor bermekimab in patients with atopic dermatitis: randomized and nonrandomized studies - PubMed, accessed September 23, 2025, https://pubmed.ncbi.nlm.nih.gov/39214920/
32. Metastatic Colorectal Cancer (MCRC) Terminated Phase 3 Trials for Bermekimab (DB14947) | DrugBank Online, accessed September 23, 2025, https://go.drugbank.com/indications/DBCOND0039029/clinical_trials/DB14947?phase=3&status=terminated
33. XBiotech's Results from Phase 2 Atopic Dermatitis Study Suggest New Drug to Treat Skin Disease - Investor Relations, accessed September 23, 2025, https://investors.xbiotech.com/news-releases/news-release-details/xbiotechs-results-phase-2-atopic-dermatitis-study-suggest-new/
34. Dupilumab Terminated Phase 2 Trials for Atopic Dermatitis Treatment | DrugBank Online, accessed September 23, 2025, https://go.drugbank.com/drugs/DB12159/clinical_trials?conditions=DBCOND0028414&phase=2&purpose=treatment&status=terminated
35. Bermekimab Successfully Treats Hidradenitis Suppurativa, Including Significant Reduction in Pain | XBiotech USA, INC., accessed September 23, 2025, https://investors.xbiotech.com/news-releases/news-release-details/bermekimab-successfully-treats-hidradenitis-suppurativa/
36. Acne Inversa Completed Phase 2 Trials for Bermekimab (DB14947) | DrugBank Online, accessed September 23, 2025, https://go.drugbank.com/indications/DBCOND0089998/clinical_trials/DB14947?phase=2&status=completed
37. A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa | ClinicalTrials.gov, accessed September 23, 2025, https://clinicaltrials.gov/study/NCT04019041?term=NCT02643654%20NCT03512275%20NCT04019041%20NCT04988308&rank=2&tab=results
38. Healthy Volunteers Completed Phase 1 Trials for Bermekimab (DB14947) - DrugBank, accessed September 23, 2025, https://go.drugbank.com/indications/DBCOND0028122/clinical_trials/DB14947?phase=1&status=completed
39. Breakthrough Results from Phase 2 Clinical Trial of Bermekimab in the Treatment of Atopic Dermatitis (AD) to be Presented on March 2, 2019 at American Academy of Dermatology Annual Meeting - Investor Relations, accessed September 23, 2025, https://investors.xbiotech.com/news-releases/news-release-details/breakthrough-results-phase-2-clinical-trial-bermekimab-treatment/
40. NCT04021862 | A Study to Evaluate the Safety and Efficacy of Bermekimab in Patients With Moderate to Severe Atopic Dermatitis | ClinicalTrials.gov, accessed September 23, 2025, https://clinicaltrials.gov/study/NCT04021862
41. Bermekimab Terminated Phase 2 Trials for Atopic Dermatitis Treatment | DrugBank Online, accessed September 23, 2025, https://go.drugbank.com/drugs/DB14947/clinical_trials?conditions=DBCOND0028414&phase=2&purpose=treatment&status=terminated
42. A Phase II, Open Label Study of Bermekimab in Patients with Hidradenitis Suppurativa Shows Resolution of Inflammatory Lesions and Pain - ResearchGate, accessed September 23, 2025, https://www.researchgate.net/publication/338895506_A_Phase_II_Open_Label_Study_of_Bermekimab_in_Patients_with_Hidradenitis_Suppurativa_Shows_Resolution_of_Inflammatory_Lesions_and_Pain
43. A Phase II Open-Label Study of Bermekimab in Patients with Hidradenitis Suppurativa Shows Resolution of Inflammatory Lesions and Pain - PubMed, accessed September 23, 2025, https://pubmed.ncbi.nlm.nih.gov/32004568/
44. Bermekimab Successfully Treats Hidradenitis Suppurativa, Including Significant Reduction in Pain - Investor Relations, accessed September 23, 2025, https://investors.xbiotech.com/node/8106/pdf
45. Phase 2 Clinical Trial of Bermekimab Shows Potential New Standard of Care for Treatment of Hidradenitis Suppurativa, Including - XBiotech, accessed September 23, 2025, https://investors.xbiotech.com/node/8126/pdf
46. A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients With Moderate to Severe Hidradenitis Suppurativa - The YODA Project, accessed September 23, 2025, https://yoda.yale.edu/clinical-trial/nct04019041-a-phase-ii-randomized-double-blind-placebo-controlled-study-of-bermekimab-in-patients-with-moderate-to-severe-hidradenitis-suppurativa/
47. XBiotech Announces European Medicines Agency (EMA) Validates Marketing Authorization Application (MAA) for Xilonix™ in the Treatment of Advanced Colorectal Cancer - Investor Relations, accessed September 23, 2025, https://investors.xbiotech.com/news-releases/news-release-details/xbiotech-announces-european-medicines-agency-ema-validates/
48. Bermekimab Biosimilar – Anti-IL1A mAb – Research Grade - ProteoGenix, accessed September 23, 2025, https://us.proteogenix.science/product/bermekimab-biosimilar-anti-il1a-mab-research-grade/
49. Bermekimab: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed September 23, 2025, https://go.drugbank.com/drugs/DB14947
50. Clinical efficacy of subcutaneous bermekimab. (a) Proportions of... - ResearchGate, accessed September 23, 2025, https://www.researchgate.net/figure/Clinical-efficacy-of-subcutaneous-bermekimab-a-Proportions-of-patients-in-Study-1-who_fig1_383565794
51. Bermekimab (Anti-IL-1a) | Safety Data Sheet - Selleck Chemicals, accessed September 23, 2025, https://www.selleckchem.com/msds/bermekimab-anti-il-1a-MSDS.html
52. Janssen Announces Completion of Acquisition of Investigational Bermekimab from XBiotech Inc. - investor.jnj.com, accessed September 23, 2025, https://www.investor.jnj.com/investor-news/news-details/2019/Janssen-Announces-Completion-of-Acquisition-of-Investigational-Bermekimab-from-XBiotech-Inc.-12-30-2019/default.aspx
53. XBiotech Closes on Sale of True Human Antibody Bermekimab to Janssen, accessed September 23, 2025, https://investors.xbiotech.com/news-releases/news-release-details/xbiotech-closes-sale-true-human-antibody-bermekimab-janssen/
54. XBiotech Inks Clinical Manufacturing Deal - Investor Relations, accessed September 23, 2025, https://investors.xbiotech.com/news-releases/news-release-details/xbiotech-inks-clinical-manufacturing-deal/
55. xbit20211231_10k.htm - SEC.gov, accessed September 23, 2025, https://www.sec.gov/Archives/edgar/data/1626878/000117184322001904/xbit20211231_10k.htm
56. securities and exchange commission - SEC.gov, accessed September 23, 2025, https://www.sec.gov/Archives/edgar/data/1626878/000117184319001708/f10k_031319p.htm
57. European Medicines Agency Archives - The Antibody Society, accessed September 23, 2025, https://www.antibodysociety.org/european-medicines-agency/
58. Australian Register of Therapeutic Goods (ARTG), accessed September 23, 2025, https://www.tga.gov.au/products/australian-register-therapeutic-goods-artg
59. Bimzelx | European Medicines Agency (EMA), accessed September 23, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/bimzelx
60. Bimzelx | Therapeutic Goods Administration (TGA), accessed September 23, 2025, https://www.tga.gov.au/resources/auspmd/bimzelx
61. 761151Orig1s000 - accessdata.fda.gov, accessed September 23, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/761151Orig1s000MultidisciplineR.pdf
62. UCB receives U.S. FDA approval for BIMZELX[®] (bimekizumab-bkzx) as the first IL-17A and IL-17F inhibitor for adults with moderate to severe hidradenitis suppurativa, accessed September 23, 2025, https://www.ucb.com/newsroom/press-releases/article/ucb-receives-us-fda-approval-for-bimzelxr-bimekizumab-bkzx-as-the-first-il-17a-and-il-17f-inhibitor-for-adults-with-moderate-to-severe-hidradenitis-suppurativa
63. Janssen to Acquire Investigational Bermekimab from XBiotech - PR Newswire, accessed September 23, 2025, https://www.prnewswire.com/news-releases/janssen-to-acquire-investigational-bermekimab-from-xbiotech-300970952.html
64. Janssen Pharmaceutica NV | Advanced machine learning for Innovative Drug Discovery (AIDD), accessed September 23, 2025, https://ai-dd.eu/janssen